A5014458484- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Biosimilars and Bioanalytical Methods
- Leprosy Research and Treatment
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Pregnancy and Medication Impact
- Gastric Cancer Management and Outcomes
- Child Nutrition and Water Access
- Infective Endocarditis Diagnosis and Management
- Gastrointestinal disorders and treatments
- Tuberculosis Research and Epidemiology
- Pericarditis and Cardiac Tamponade
- Mycobacterium research and diagnosis
- Gastrointestinal Bleeding Diagnosis and Treatment
- Liver Diseases and Immunity
- IL-33, ST2, and ILC Pathways
- Viral-associated cancers and disorders
- Dysphagia Assessment and Management
- Diverse Approaches in Healthcare and Education Studies
- Colorectal and Anal Carcinomas
- Viral Infections and Immunology Research
- Health Systems, Economic Evaluations, Quality of Life
- Kawasaki Disease and Coronary Complications
Camden and Campbelltown Hospitals
2021-2024
Western Sydney University
2023-2024
Canterbury Hospital
2024
Concord Repatriation General Hospital
2014-2024
Weatherford College
2023
Macquarie University
2023
The University of Sydney
2020-2022
Concord Hospital
2014-2016
UNSW Sydney
2012-2015
Bankstown Lidcombe Hospital
2015
<h3>Objective</h3> The rising incidence of inflammatory bowel disease in Asia supports the importance environmental risk factors aetiology. This prospective population-based case-control study Asia-Pacific examined prior to patients developing IBD. <h3>Design</h3> 442 incident cases (186 Crohn9s (CD); 256 UC; 374 Asians) diagnosed between 2011 and 2013 from eight countries Australia 940 controls (frequency-matched by sex, age geographical location; 789 completed an factor questionnaire at...
The expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges treatment selection. Persistence analysis assesses drug durability real-world settings, acting as a surrogate marker medication efficacy tolerance. Unlike traditional comparative studies, persistence provides insights extending beyond the initial year of treatment.
Summary Background Medication persistence contributes real‐world evidence about treatment effectiveness, tolerability and prescriber patient acceptability. Aims To evaluate of biological agents in Crohn's disease (CD) ulcerative colitis (UC) the effects immunomodulator use lines. Methods Retrospective national population‐based data on for adalimumab, infliximab vedolizumab ustekinumab CD UC were analysed from Australian Pharmaceutical Benefits Scheme using Kaplan‐Meier analysis Cox...
Inflammatory bowel diseases (IBD) may result in disability. We aim to validate a novel scoring system for the IBD disability index (IBD-DI), and identify predictors of its correlation with work absenteeism. This prospective ambulatory clinic cohort study measured IBD-DI, Crohn's Disease Activity Index (CDAI) disease (CD) or partial Mayo score (pMayo) ulcerative colitis (UC), IBDQ quality-of-life, Work Productivity Impairment. Negative IBD-DI represented greater Validation tests were...
The choice between infliximab (IFX) and vedolizumab (VED) as a first-line biological agent in moderate-to-severe ulcerative colitis (UC) can be difficult. Second-line efficacy may decline following prior treatment failure UC patients. However, it is not known whether second-line IFX declines after of VED.We aimed to compare persistence VED, particular VED.Persistence VED was analysed from the Australian Pharmaceutical Benefits Scheme registry data either first- or UC. Propensity score...
INTRODUCTION: Comparative effectiveness research provides data on the relative benefits and risks between treatments. In Crohn's disease (CD), however, there are few head-to-head studies comparing advanced therapies none with long-term follow-up. Real-world effectiveness, defined by treatment persistence, obtained from prospective population-based patient cohorts, may help determine best sequencing positioning of biological agents. METHODS: We analyzed prospectively collected Australian...
Background/Aims To examine the association between use of oral contraceptive pills (OCPs) and risk developing inflammatory bowel diseases (IBD), in a modern cohort. Methods A prospective nested case-control study across sites Asia-Pacific region was conducted; involving female IBD cases asymptomatic controls. Subjects completed questionnaire addressing questions related to OCP use. Primary outcome development those exposed versus non-exposure. Secondary outcomes were Crohn's disease (CD)...
Supporting Information Video S1 showing index transthoracic echocardiography, demonstrating moderately reduced left ventricular systolic function, and serial marked improved of function Please note: The publisher is not responsible for the content or functionality any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.
Abstract Background Treatment persistence (duration of medication use) provides real-world evidence on therapeutic effectiveness, tolerability and prescriber patient preferences. Biological agent in Crohn’s disease (CD) ulcerative colitis (UC) was compared from a national population-based registry with no hierarchical prescribing order. We hypothesised immunotherapy co-therapy would increase for anti-TNF agents, but not non-anti-TNF agents due to reduced immunogenicity. Methods A randomly...
Clinical: Diagnosis and outcome S57 Conclusions: Vitamin D deficiency is common in CD patients, but also healthy controls.For ethnicity, never using a solarium azathioprine use are associated with vitamin levels.Appropriate screening, the importance of dietary intake sunlight exposure should be stressed to both patients normal population.
Inflammatory bowel disease (IBD) experienced a rapid rise in incidence and prevalence developing countries that parallels rates of accelerated industrialization these regions.1 Migrant studies can investigate the epidemiological factors driving this change. Migrants form unique population for investigating evolving pattern IBD globally. Groups migrating from areas low to high will experience shorter time period between risk factor exposure onset. This is relevant those related lifestyle...
Introduction: Mr PH is a 33 yo man who was diagnosed with Ulcerative colitis (UC) in January 2021. He commenced on prednisone enema and mesalazine 4.8g partial improvement of symptoms. Case description/methods: returned to our clinic month later February 2021 new pleuritic chest pain. febrile 38.2 deg tachycardic 110 bpm. An ECG showed normal sinus rhythm but had widespread ST elevation PR depression. His cardiac enzyme troponin elevated 122ng/L (normal < 15) diagnosis pericarditis...